Australian Clinical Labs Ltd
ACL
Company Profile
Business description
Australian Clinical Labs, or ACL, is Australia’s third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.
Contact
1868-1892 Dandenong Road
ClaytonVIC3168
AUST: +61 300453688
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2025
Employees
4,900
Australian Clinical Labs Ltd News & Analysis
stocks
Market is underestimating ASX pathology shares
Morningstar sees several reasons to expect a stronger recover than market consensus.
stocks
3 ASX small caps with bright futures
Simon Conn of Investors Mutual says small caps are poised for a turnaround and there are three stocks that he likes right now.
markets
Why this bull market can't last
Schroders' Australian equity team say investors piling into tech stocks again are ignoring a turning point in markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,633.10 | 66.10 | 0.77% |
| CAC 40 | 7,255.01 | 41.69 | 0.58% |
| DAX 40 | 19,322.59 | 176.42 | 0.92% |
| Dow JONES (US) | 44,296.51 | 426.16 | 0.97% |
| FTSE 100 | 8,262.08 | 112.81 | 1.38% |
| HKSE | 19,229.97 | 371.14 | -1.89% |
| NASDAQ | 19,003.65 | 31.23 | 0.16% |
| Nikkei 225 | 38,283.85 | 257.68 | 0.68% |
| NZX 50 Index | 13,041.90 | 276.66 | 2.17% |
| S&P 500 | 5,969.34 | 20.63 | 0.35% |
| S&P/ASX 200 | 8,393.80 | 70.80 | 0.85% |
| SSE Composite Index | 3,267.19 | 103.21 | -3.06% |